DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
ASUNCTIS
A randomized phase 2
trial of enzalutamide and talazoparib in metastatic
hormone-naïve prostate cancer
PROSTATE
ASCO
2026
ZZ-FIRST
A randomized phase 2
trial of enzalutamide and talazoparib in metastatic
hormone-naïve prostate cancer
PROSTATE
ASCO
2026
CADILLAC
Camizestrant plus ribociclib in hormone receptor-positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial
BREAST
ASCO
2026
MIRROR
Artificial Intelligence for clinical data extraction from EHRs in breast cancer trials: The MIRROR study
BREAST
(Journal) npj Breast Cancer
2026
ADELA
Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
BREAST
ASCO
2026
PHERGAIN2
A Chemotherapy-Free, Pathological Response-Adapted Strategy Using Trastuzumab-Pertuzumab and T-DM1 in HER2-Positive Early Breast Cancer: the PHERGAIN-2 study”
BREAST
(Journal) Annals of Oncology
2026
PHERGAIN
SUBSTUDY - PHERGuide: 5-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in HER2[+] early breast cancer (EBC) patients (pts)
BREAST
ESMO Breast
2026
I3LUNG
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
LUNG
(Journal) Nature Medicine
2026
PATHFINDER
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
BREAST
(Journal) Breast Cancer Research
2025
EMPRESS
Reoperative window-of-opportunity study with giredestrant or tamoxifen in premenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative and Ki67≥10% early breast cancer
BREAST
ESMO
2025
ATRACTIB
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment 1 of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
BREAST
(Journal) Nature Medicine
2025
DEBBRAH
SUBSTUDY - CEBBRAH: Translational analysis of cerebrospinal fluid (CSF) and plasma circulating tumor DNA (ctDNA) from breast cancer patients (pts) with leptomeningeal disease (LMD) treated with trastuzumab deruxtecan (T-DXd) in the DEBBRAH trial
BREAST
SABCS
2025
Other MEDSIR related articles
"